Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.77 |
| ▸ | MEN1 | O00255 | 10/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 7/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | BLM | P54132 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17466932 | 0.88 | MAPT (1.00) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL17466936 | 0.81 | MAPT (0.85) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL1238796 | 0.79 | MEN1 (1.00) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL17466941 | 0.78 | MAPT (0.71) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL20824922 | 0.78 | KMT2A (0.80) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL3369467 | 0.77 | KMT2A (0.77) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL9591757 | 0.77 | MAPT (0.77) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL21887201 | 0.77 | MAPT (0.77) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL6824611 | 0.77 | KMT2A (0.77) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL987696 | 0.77 | MAPT (0.77) | MAPTALDH1A1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | claimed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | claimed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | claimed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | claimed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| EP-1068176-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | Jomaa, Hassan (DE) | 2001-01-17 | — | — | EP | claimed |
| WO-2000027803-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | JOMAA, HASSAN (DE) | 2000-05-18 | — | — | WO | claimed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1068176-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | Jomaa, Hassan (DE) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000027803-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | JOMAA, HASSAN (DE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | MAPT 4832/4885ALDH1A1 1419/4885KMT2A 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.